135 related articles for article (PubMed ID: 36250610)
1. Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy.
Xu J; Chen T; Sun T; Yu C; Yan D; Zhu L
Biomater Sci; 2022 Nov; 10(22):6601-6613. PubMed ID: 36250610
[TBL] [Abstract][Full Text] [Related]
2. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy.
Chen T; Xu J; Zhu L; Yan D
Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999
[TBL] [Abstract][Full Text] [Related]
3. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of Ovarian Cancer.
Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D
ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905
[TBL] [Abstract][Full Text] [Related]
4. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
5. Electrostatic Attractive Self-Delivery of siRNA and Light-Induced Self-Escape for Synergistic Gene Therapy.
Yang Y; Ning H; Xia T; Du J; Sun W; Fan J; Peng X
Adv Mater; 2023 Jul; 35(30):e2301409. PubMed ID: 37084041
[TBL] [Abstract][Full Text] [Related]
6. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte Membrane-Wrapped pH Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Gao L; Wang H; Nan L; Peng T; Sun L; Zhou J; Xiao Y; Wang J; Sun J; Lu W; Zhang L; Yan Z; Yu L; Wang Y
Bioconjug Chem; 2017 Oct; 28(10):2591-2598. PubMed ID: 28872851
[TBL] [Abstract][Full Text] [Related]
8. A RBC membrane-camouflaged biomimetic nanoplatform for enhanced chemo-photothermal therapy of cervical cancer.
Luo L; Zeng F; Xie J; Fan J; Xiao S; Wang Z; Xie H; Liu B
J Mater Chem B; 2020 May; 8(18):4080-4092. PubMed ID: 32239064
[TBL] [Abstract][Full Text] [Related]
9. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
10. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
11. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
12. PEGylated cationic nanoassemblies based on triblock copolymers to combine siRNA therapeutics with anticancer drugs.
Conte C; Dal Poggetto G; Schiano Di Cola V; Russo A; Ungaro F; Russo G; Laurienzo P; Quaglia F
Biomater Sci; 2021 Sep; 9(18):6251-6265. PubMed ID: 34369494
[TBL] [Abstract][Full Text] [Related]
13. A self-amplified ROS-responsive chemodrug-inhibitor conjugate for multi-drug resistance tumor therapy.
Sun T; Xu J; Chen T; Tu C; Zhu L; Yan D
Biomater Sci; 2022 Feb; 10(4):997-1007. PubMed ID: 35044379
[TBL] [Abstract][Full Text] [Related]
14. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles.
Liu Y; Song Z; Zheng N; Nagasaka K; Yin L; Cheng J
Nanoscale; 2018 Aug; 10(32):15339-15349. PubMed ID: 30070662
[TBL] [Abstract][Full Text] [Related]
15. pH-responsive DNA nanomicelles for chemo-gene synergetic therapy of anaplastic large cell lymphoma.
Li Y; Yue S; Cao J; Zhu C; Wang Y; Hai X; Song W; Bi S
Theranostics; 2020; 10(18):8250-8263. PubMed ID: 32724469
[TBL] [Abstract][Full Text] [Related]
16. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
17. Visible light-switched cytosol release of siRNA by amphiphilic fullerene derivative to enhance RNAi efficacy in vitro and in vivo.
Wang J; Xie L; Wang T; Wu F; Meng J; Liu J; Xu H
Acta Biomater; 2017 Sep; 59():158-169. PubMed ID: 28511875
[TBL] [Abstract][Full Text] [Related]
18. The alpha-adrenergic antagonist prazosin promotes cytosolic siRNA delivery from lysosomal compartments.
Van de Vyver T; Muntean C; Efimova I; Krysko DV; De Backer L; De Smedt SC; Raemdonck K
J Control Release; 2023 Dec; 364():142-158. PubMed ID: 37816483
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
